Search hospitals > Illinois > Chicago
University of Chicago Comprehensive Cancer Center
Claim this profileChicago, Illinois 60637
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Tumors
Conducts research for Leukemia
Conducts research for Lymphoma
594 reported clinical trials
50 medical researchers
Summary
University of Chicago Comprehensive Cancer Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Recurrence, Tumors, Leukemia, Lymphoma and other specialties. University of Chicago Comprehensive Cancer Center is involved with conducting 594 clinical trials across 769 conditions. There are 50 research doctors associated with this hospital, such as Rita Nanda, MD, Susan L. Cohn, Ardaman Shergill, MD, and Christine M. Bestvina.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Recurrence
Global LeaderStage IV
Stage III
Stage I
Top PIs
Rita Nanda, MDUniversity of Chicago Comprehensive Cancer Center7 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
24 reported clinical trials
47 drugs studied
Susan L. CohnUniversity of Chicago Comprehensive Cancer Center7 years of reported clinical research
Expert in Neuroblastoma
Expert in Tumors
19 reported clinical trials
38 drugs studied
Ardaman Shergill, MDUniversity of Chicago Comprehensive Cancer Center3 years of reported clinical research
Studies Colorectal Cancer
Studies Adenocarcinoma
23 reported clinical trials
61 drugs studied
Christine M. BestvinaUniversity of Chicago Comprehensive Cancer Center5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
18 reported clinical trials
33 drugs studied
Clinical Trials running at University of Chicago Comprehensive Cancer Center
Breast Cancer
Prostate Cancer
Cancer
Lung Cancer
Acute Myeloid Leukemia
Lymphoma
Leukemia
Acute Lymphoblastic Leukemia
Tumors
Brain Tumor
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Chicago Comprehensive Cancer Center?
University of Chicago Comprehensive Cancer Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Recurrence, Tumors, Leukemia, Lymphoma and other specialties. University of Chicago Comprehensive Cancer Center is involved with conducting 594 clinical trials across 769 conditions. There are 50 research doctors associated with this hospital, such as Rita Nanda, MD, Susan L. Cohn, Ardaman Shergill, MD, and Christine M. Bestvina.
Where is University of Chicago Comprehensive Cancer Center located?
**Directions to the Center for Care and Discovery:**
- From the north, take the Kennedy Expressway (I-90) east or Edens Expressway (I-94) south.
- Merge onto the Dan Ryan Expressway (I-90/94) east.
- Exit at 55th Street (Garfield Boulevard) and follow signs to 5700 S. Maryland Ave.
Who should I call to ask about financial aid or insurance network?
For insurance inquiries at the University of Chicago Comprehensive Cancer Center, email Benefits@uchicago.edu or call 773-702-9634. For financial assistance, download the application in English or Spanish, attach supporting documents, and mail to The University of Chicago Medicine, 150 Harvester Dr., Ste 300, Burr Ridge, IL 60527-5965. For billing questions, contact (773) 702-6664 or send mail to the same address.
What insurance does University of Chicago Comprehensive Cancer Center accept?
The University of Chicago Comprehensive Cancer Center accepts a broad spectrum of insurance plans, such as Aetna, AIG Medical, American Health Holding, Blue Cross Blue Shield PPO, Cigna, Coventry Health Care of Illinois (PersonalCare) HMO, Health Alliance PPO, Humana, Medicaid (Illinois), Medicare, MultiPlan PPO, and United Healthcare Choice Plus (POS/PPO). This includes commercial insurance plans, exchange or health insurance marketplace plans, and Medicare and Medicare Advantage insurance plans. Please contact your insurance company to confirm coverage before receiving services.
What awards or recognition has University of Chicago Comprehensive Cancer Center received?
The University of Chicago Comprehensive Cancer Center (UCCCC) has been an NCI-Designated Cancer Center since 1973 and achieved comprehensive status in 2008. It is renowned for its contributions to basic and clinical research, especially in drug development and early-phase clinical trials, enrolling about 1,000 patients annually. The center excels in genetic classification of hematological malignancies, cancer immunology, pharmacogenomics, and cancer genetics, among other areas, and has earned significant accolades including the Leapfrog Group's Top Teaching Hospital and the Magnet Recognition Program designation.